Efficacy and Safety of Novel Continuous Subcutaneous Levodopa Infusion Therapies ND0612 and ABBV-951 for Parkinson's Disease: A Systematic Review.

IntroductionRecent research in Parkinson's disease (PD) has highlighted the potential therapies of continuous subcutaneous infusions (CSCI) of levodopa/carbidopa (ND0612) and foslevodopa/foscarbidopa (ABBV-951). This systematic review aims to explore their effectiveness and safety for PD.MethodsGuided by the PRISMA statement, we systematically searched 3 electronic databases: MEDLINE, Embase, and Cochrane Central. We combined quantitative and qualitative data for synthesis and descriptive analysis. Quality assessment and risk of bias were evaluated by ROBINS-1 and Rob-2 criteria.ResultsWe included 6 records with a total of 698 patients. CSCI therapies reduced motor symptoms in PD patients with levodopa-related motor fluctuations and clinical improvements. Infusions-site reactions were the main adverse event recorded.ConclusionsND0612 and ABBV-951 are promising options for enhancing motor control and quality of life in PD patients. However, further research is needed to assess long-term efficacy, safety, and comparisons with oral levodopa and device-aided treatments.